Linking HIV-infected persons of color and injection drug users to HIV medical and other services: The California Bridge Project

AIDS Patient Care and STDs

Volumn 19, Issue 6, 2005, Pages 406-412

  Molitor, Fred ^a   Kuenneth, Christina ^b   Waltermeyer, Jenny ^a   Mendoza, Marisol ^a   Aguirre, Arthur ^a   Brockmann, Kama ^c   Crump, Carol ^c  

^a ETR ASSOCIATES   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CALIFORNIA DEPARTMENT OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ZIDOVUDINE;

ADULT; ARTICLE; DRUG USE; ETHNIC DIFFERENCE; FEMALE; GROUP PSYCHOLOGY; HEALTH EDUCATION; HEALTH PROGRAM; HEALTH PROMOTION; HEALTH SERVICE; HETEROSEXUALITY; HOMOSEXUALITY; HOUSING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RISK; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; PATIENT COUNSELING; PATIENT REFERRAL; PSYCHOTHERAPY; RISK ASSESSMENT; SEXUAL BEHAVIOR; SEXUALITY; UNITED STATES;

ADULT; AFRICAN AMERICANS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ATTITUDE TO HEALTH; CALIFORNIA; COHORT STUDIES; COMMUNITY HEALTH SERVICES; FEMALE; FOLLOW-UP STUDIES; HEALTH SERVICES ACCESSIBILITY; HISPANIC AMERICANS; HIV INFECTIONS; HUMANS; INTERVENTION STUDIES; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 21844460770     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2005.19.406     Document Type: Article

References (21)

1. Fleming PL, Byers RH, Sweeney PA, Daniels D, Karon JM, Janssen RS. HIV Prevalence in the United States, 2000. Paper presented at 9th Conference on Retroviruses and Opportunistic Infections; Oral abstract, session 5, presentation 11. Seattle, WA: February 24-28, 2002.
2. Centers for Disease Control and Prevention. A Glance at the HIV Epidemic. www.cdc.gov/nchstp/od/news/At-a-Glance.pdf. (Last accessed March 17, 2004).
3. Stein MD, Piette J, Mor V, et al. Differences in access to zidovudine (AZT) among symptomatic HIV-infected persons. J Gen Intern Med 1991;6:35-40.
4. Stone VE, Mauch MY, Steger K, Janas SF, Craven DE. Race, gender, drug use, and participation in AIDS clinical trials. Lessons from a municipal hospital cohort. J Gen Intern Med 1997;12:150-157.
5. Diaz T, Chu SY, Sorvillo F, et al. Differences in participation in experimental drug trials among persons with AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10:562-568.
6. Moore RD, Stanton D, Gopalan R, Chaisson RE. Racial differences in the use of drug therapy for HIV disease in an urban community. N Engl J Med 1994;330: 763-768.
7. Andersen R, Bozzette S, Shapiro M, et al. Access of vulnerable groups to antiretroviral therapy among persons in care for HIV disease in the United States. Health Serv Res 2000;35:389-416.
8. Gifford AL, Cunningham WE, Heslin KC, et al. Participation in research and access to experimental treatments by HIV-infected patients. N Engl J Med 2002; 346:1373-1382.
9. Palacio H, Kahn JG, Richards TA, Morin SF. Effect of race and/or ethnicity in use of antiretrovirals and prophylaxis for opportunistic infection: A review of the literature. Public Health Rep 2002;117:233-251.
10. Wong MD, Cunningham WE, Shapiro MF, et al. Disparities in HIV treatment and physician attitudes about delaying protease inhibitors for nonadherent patients. J Gen Intern Med 2004;19:366-374.
11. Turner BJ, Cunningham WE, Duan N, et al. Delayed medical care after diagnosis in a US national probability sample of persons infected with human immunodeficiency virus. Arch Intern Med 2000;160:2614-2622.
12. Samet JH, Freeberg KA, Stein MD, et al. Time from testing positive for HIV to presentation for primary care. Arch Intern Med 1998;158:734-740.
13. Stein MD, Piette J, Mor V, et al. Differences in access to zidovudine (AZT) among symptomatic HIV-infected persons. J Gen Intern Med 1991;6:35-40.
14. Stone VE, Mauch MY, Steger K, Janas SF, Craven DE. Race, gender, drug use, and participation in AIDS clinical trials. Lessons from a municipal hospital cohort. J Gen Intern Med 1997;12:150-157.
15. Crump C, Brockmann K, Molitor F. Prevention with positives in California: The Early Intervention Program, The HIV Transmission Prevention Project and the Bridge Project. Presented at 2003 National HIV Prevention Conference. Atlanta, GA: July 27-30, 2003.
16. California Department of Health Services, Office of AIDS. California HIV case surveillance report: cases reported through September 30, 2004. www.dhs. ca.gov/ps/ooa/Statistics/pdf/Stats2004/sep04HIV merged.pdf (Last accessed March 17, 2004).
17. Denning P. Harm reduction psychotherapy: An innovative alternative to classical addictions theory. Am Clin Lab 2002;21:16-18.
18. Marlatt G, Witkiewitz K. Harm reduction approaches to alcohol use: health promotion, prevention and treatment. Addict Behav 2002;27:867-886.
19. Molitor F, Mendoza M, Wagler D, Kuenneth C. The HIV Transmission Prevention Project (HTPP) and Risk Reduction mong HIV-Negative and HIV-Positive Persons at High-Risk for HIV Transmission. www.preventioncasemanagement.org/ HTPP2004. pdf (Last accessed March 17, 2004).
20. Bird ST, Bogart LM, Delahanty DL. Health-related correlates of perceived discrimination in HIV care. AIDS Patient Care STDS 2004;18:19-26.
21. Blair JM, Fleming PL, Karon JM. Trends in AIDS incidence and survival among racial/ethnic minority men who have sex with men, United States, 1990-1999. J Acquir Immune Defic Syndr 2002;31:339-347.